Zabner 2009.

Methods	Double‐blind (participant, caregiver, investigator), parallel assignment, safety/efficacy RCT.
Participants	People with CF aged 16 years or older.
Interventions	Intervention: hypertonic xylitol. Control: hypertonic saline.
Outcomes	Primary outcome measures: FEV1 change from baseline, adverse events and respiratory symptom score at 14 days. Secondary outcome measures: density of colonization/g of sputum, time to next exacerbation, sputum cytokines and revised CF QoL questionnaire at 14 days.
Notes	Marked as completed on clinicaltrials.gov.

CaEDTA: calcium ethylene diamine tetra‐acetate
CF: cystic fibrosis
IPD: individual patient data
QoL: quality of life
RCT: randomised controlled trial